JIPMER Nursing Office…: H2 blocker of choice, in liver disease is

JIPMER Nursing Officer-2017

Pharmacology

Hard

Appeared in: JIPMER Nursing Officer-2017

Explanation

Nizatidine is the H2 blocker of choice for patients with liver disease due to its unique pharmacokinetic profile.
It undergoes minimal first-pass metabolism in the liver, which results in high bioavailability and less strain on the compromised organ.
Its primary route of elimination is renal, with the majority of the drug excreted unchanged in the urine, making its clearance predictable and safe in hepatic dysfunction.

Option A: Cimetidine is extensively metabolized by the liver and is a potent inhibitor of the cytochrome P450 enzyme system, which significantly increases the risk of drug toxicity and interactions in patients with liver disease.
Option B: Ranitidine undergoes significant first-pass hepatic metabolism. Its clearance is reduced in patients with liver dysfunction, leading to potential accumulation and adverse effects.
Option C: Although Famotidine is a relatively safe option with no significant P450 interactions, it still undergoes partial hepatic metabolism. Nizatidine's almost exclusive reliance on renal clearance makes it a theoretically safer and more predictable choice in severe liver disease.

Clinical Relevance

Nursing practice connection: Knowing Pharmacokinetics of H2 Blockers in Hepatic Impairment helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Nurses must always consider patient comorbidities, such as liver or kidney disease, when administering medications. Impaired organ function can lead to drug accumulation and toxicity.
It is a critical nursing responsibility to monitor liver function tests (e.g., ALT, AST, bilirubin) and assess for signs of drug toxicity (e.g., jaundice, altered mental status, pruritus) in patients with hepatic impairment.
What if? If the patient had severe renal disease instead of liver disease, Nizatidine would be the least desirable choice. Its dose would require significant reduction, and an agent with more hepatic clearance, like Famotidine, might be preferred.

How to Approach the Question

First, identify the core components of the question: the drug class (H2 blockers) and the specific patient population (those with liver disease).
The question asks for the 'drug of choice,' which implies selecting the safest and most effective option for this specific condition.
The key to answering this question lies in understanding the pharmacokinetics of the drugs—specifically, how they are metabolized and eliminated from the body.
For a patient with liver disease, the ideal drug should have minimal dependence on the liver for its metabolism and clearance.
Compare the metabolic profiles of the four options. Recall or deduce that Cimetidine and Ranitidine have significant hepatic metabolism, while Famotidine and Nizatidine have less.
Between the safer options, recall that Nizatidine is notable for having the least hepatic metabolism and being primarily cleared by the kidneys, making it the most suitable choice.

Concept Tested & Keywords

QMPIMTj8GPNPhthbL2N-ih

E6 Pharmacology KD Tripathi Essentials 9e Part 2 p. 324-326

E6 Pharmacology Nursing Lilley 11e Part 3 p. 167-169